Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25835351 | 0.84 | BACE1 (0.39) | PTPRCGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL25835376 | 0.82 | TDP2 (0.34) | MAPTMEN1KMT2APOLB | |
| SCHEMBL25835354 | 0.80 | BACE1 (0.50) | GAAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL25836945 | 0.71 | PTGS2 (0.35) | GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL25834696 | 0.70 | PTPRC (0.37) | PTPRCGAAMAPTMEN1KMT2A | |
| SCHEMBL25835356 | 0.69 | HDAC4 (0.46) | GAAALDH1A1LMNABRD4 | |
| SCHEMBL25834368 | 0.67 | PTPRC (0.34) | PTPRCGAAMAPTMEN1KMT2A | |
| SCHEMBL12646071 | 0.59 | — | — | |
| SCHEMBL14535145 | 0.59 | — | — | |
| SCHEMBL13528150 | 0.59 | TLR4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227393-A1 | IRON CATALYZED HIGHLY ENANTIOSELECTIVE CIS-DIHYDROXYLATION OF QUINONES | THE UNIVERSITY OF HONG KONG (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227393-A1 | IRON CATALYZED HIGHLY ENANTIOSELECTIVE CIS-DIHYDROXYLATION OF QUINONES | NFE2L2, DUOX1, DUOX2 | PTPRC 3535/4885SLC6A3 766/4885GAA 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.